New congestion lanes to open on I-4 by the end of April
KISSIMMEE, Fla. (WFLA)— Governor Ron DeSantis held a press conference with Florida Department of Transportation Secretary Jared Perdue in Kissimmee Monday morning.
The governor discussed projects related to the Moving Florida Forward initiative, which aims to accelerate construction on critical roadways across the state.
'We have at least 20 major interstate and roadway projects that have been expedited through Moving Florida Forward,' he said.
DeSantis highlighted some of the major projects underway: the addition of regular and express lanes on I-275 in Pinellas County, the redesign of Golden Glades interchange on I-95 in Miami, reconstruction of the Fruitville interchange on I-75 in Sarasota County, the widening of US-98 in Bay County and the addition of auxiliary lanes to I-75 in Ocala.
The conference on Monday served as an announcement of the upcoming completion of another major project, the addition of congestion relief lanes to one of the busiest sections of I-4 between Polk and Osceola Counties.
The new relief lanes will open the week of April 28, which DeSantis emphasized was eight months ahead of schedule.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@
Yahoo
30 minutes ago
- Yahoo
Studio 17 Spotlights Kern County SHRM Annual Conference
Presented by: Kern County SHRM On today's Studio 17, Kait Hill spoke with with Jackie Andrade, Conference Director, and Sky Newton, Conference Vice Chair, from Kern County SHRM to discuss their upcoming annual conference. Kern County SHRM plays a key role in connecting the local business community through leadership, professional development, and networking. With a long-standing presence in the region, Kern County SHRM's conference promises powerful keynote speakers and fresh topics that reflect the evolving workplace. The event welcomes not only HR professionals but anyone interested in career growth and leadership skills. Attendees can look forward to dynamic sessions and a vibrant atmosphere that encourages learning and connection. For those wanting to get involved year-round or register for the conference, more information is available on the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
30 minutes ago
- Yahoo
New super PAC launches anti-Mamdani ad push amid criticism over pro-Palestinian stance
NEW YORK — A group of executives in New York's finance, law and communications sectors has launched a new super PAC to oppose Zohran Mamdani's mayoral run, kicking off with an ad accusing the socialist of pushing to 'defund the police' amid an increase in pro-Palestinian protests in the city. The PAC, called Sensible City, Inc., disclosed in filings released Tuesday it has raised $211,000 so far to oppose Mamdani, who has consistently polled as the runner-up to Andrew Cuomo, the favorite to win the June 24 Democratic mayoral primary. The ad's focus on pro-Palestinian protests comes as Cuomo and other moderate Democrats have accused Mamdani of aligning himself with antisemitic causes due to his outspoken criticism of Israel's war in Gaza. Mamdani has rejected those accusations as politically motivated, saying he's adamant about fighting all forms of hate. Asked if he recognizes Israel's right to exist as a Jewish state, Mamdani has said Israel has a right to exist as a state with 'equal rights for all.' The PAC was launched by Alan Sash and Daniel Horwitz, partners at two prominent New York law firms, as well as investor Eric Eve and PR professional Lisa Wolford, paperwork shows. The largest single donation to the PAC to date came from Rob Stavis, a partner of Bessemer, a venture capital firm, who gave $100,000. Other contributors include Eagle Capital Management founder Ravenel Curry, who gave $50,000, and designer Danyelle Freeman, who also gave $50,000. Filings show the PAC has already plunked down $100,524 on airing the new ad slamming Mamdani. The ad started going out on digital platforms over the weekend. 'It doesn't stop: day after day, streets blocked, demonstrations, some calling for killing, destruction, it's not safe. Institution walls defaced with symbols to remind us of what can happen only because of who we are. The haters mean every word they utter. What can we do?' a voice in the digital ad says as imagery flashes across the screen of pro-Palestinian protests and anti-Israel vandalism playing out on New York City streets. 'Zohran Mamdani wants to defund the police, we need a mayor who puts more cops on the street. What's your June 24 Democratic primary choice?' A rep for the new PAC didn't immediately return a request for comment from the Daily News. Mamdani, a Queens Assembly member and democratic socialist, has in the past supported calls for defunding the police. As a mayoral candidate on the 2025 campaign trail, he has called for keeping NYPD staffing levels flat. Mamdani spokesman Andrew Epstein called the new PAC expenditure a 'desperate' attempt to push back on the candidate's left-wing agenda, which includes vows to increase taxes on corporations and millionaires to bankroll expanded free child care and public transit. 'It's always amusing when some of the richest people in the city are so outraged at the idea of paying just a little more in taxes that they spend tens of thousands of dollars on deceitful and slanderous attack ads,' Epstein said. 'New Yorkers will see this for exactly what it is: desperate.' The new PAC spending comes as recent polls have shown Mamdani closing in on Cuomo. A May 28 poll from Emerson University put Mamdani just 8% behind Cuomo. A separate PAC, Fix the City, has raised more than $12 million, mostly from billionaires and powerful business executives, to boost Cuomo with ads and other political messaging. The Fix the City expenditure is the largest super PAC spend on a single election in New York history. _____
